![]() ![]() The meeting brings cancer stakeholders together to raise awareness on the impact of cancer, inform the community about the advances in cancer prevention, early detection, equitable access to care and quality of life in survivorship and palliative care. will also be speaking at the Annual Hawaiʻi Comprehensive Cancer Coalition Meeting on Friday, May 26 from 9 a.m. Learn more about Henrietta Lacks.Īnnual Hawaii Comprehensive Cancer Coalition MeetingĪlfred Lacks Carter, Jr. will be speaking on Henrietta’s everlasting legacy and impact in Hawaiʻi. This will be the first time Alfred Lacks Carter, Jr. HeLa cells contributed to the discovery of human HPV causing cervical cancer and the creation of the HPV vaccine, the human immunodeficiency virus (HIV), Nobel Prize-winning developments of the polio vaccines, and much more. HeLa cells quickly made a global impact-they were distributed to researchers across the world, even into space, resulting in substantial advances in research and medicine. They named these cells “HeLa” after the first two letters of her first and last name. Her cells were the first immortal line of human cells that double every 24 hours, allowing researchers to have an indefinite replenishment of these cells to study. ![]() Researchers took samples of Herietta’s cancerous tumor during her treatment and were shocked at their discovery. Lacks died only eight months after her cancer diagnosis on October 4, 1951. Her cancer was terminal, and unfortunately, at 31 years of age, took her life, despite undergoing treatment. Henrietta Lacks was diagnosed with cervical cancer after experiencing constant pain and extensive vaginal bleeding. They have been critical to research on the prevention, early detection, and treatment of HPV-related cancers including the development of the HPV vaccines used today.” “HeLa cells have been widely used in research on cervical cancer and other cancers caused by HPV (human papillomaviruses). “Henrietta Lacks left a legacy that has impacted research in Hawaiʻi and throughout the world,” said Brenda Hernandez, UH Cancer Center researcher. If attending in person, please RSVP by calling (808) 564-5835. This free event is open to the public and will take place at the UH Cancer Center’s Sullivan Conference Center and via Zoom on Saturday, May 27 from 9:30 to 11 a.m. The summit provided recommendations and suggested strategies for future initiatives designed to increase the representation of minority individuals in dermatology clinical trials.Henrietta Lacks' grandson, Alfred Lacks Carter, Jr., will be visiting the University of Hawaiʻi Cancer Center to give a talk to honor his grandmother and the remarkable research advances made possible by her HeLa cells. The program hosted thought-provoking panel talks and discussions with various stakeholder groups, including a keynote presentation from the family of Henrietta Lacks.Ĭonclusions and Relevance Panel discussions and insightful presentations from physicians, industry leaders, community trailblazers, and patients fostered new collaborations. Observations The summit focused on 3 principal areas: (1) understanding the current clinical trials landscape (2) breaking down patient, clinician, industry, and regulatory barriers and (3) effecting change through a diversity-focused strategy. ![]() The summit was an interactive and collaborative effort to advance discussions regarding the need for broader inclusion of racial and ethnic minority patients in dermatology clinical trials. The Skin of Color Society hosted the inaugural Meeting the Challenge Summit: Diversity in Dermatology Clinical Trials in Washington, DC, from June 10 to 11, 2022. A diverse participant pool in dermatology clinical trials is critical to ensure that results are generalizable among the patient population who will ultimately depend on the efficacy of the intervention. Importance Clinical trials remain the cornerstone for determining the safety and efficacy of an intervention. ![]()
0 Comments
Leave a Reply. |